Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Uterine Cervical Neoplasms 8Squamous Cell Carcinoma of Head and Neck 6Stomach Neoplasms 5Triple Negative Breast Neoplasms 4Carcinoma, Renal Cell 4Advanced Solid Tumors 4Urinary Bladder Neoplasms 3Recurrence 3Pancreatic Neoplasms 3Melanoma 3Lung Neoplasms 3Solid Tumor 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Kidney Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Breast Neoplasms 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urothelial Bladder Carcinoma 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Solid Tumors 1Solid Tumor, Unspecified, Adult 1Sarcoma 1

Interventions

zimberelimab 1rucaparib 1Tomography, X-Ray Computed 1Irinotecan 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor, Unspecified, Adult × zimberelimab × Clear all
NCT03628677 2025-02-04

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

Arcus Biosciences, Inc.

Phase 1 Completed
75 enrolled
Other solid neoplasm

Solid Tumor, Unspecified, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡